OBJECTIVES: We assessed the relationship between individual characteristics and receipt of oseltamivir (Tamiflu) in the United States during the H1N1 pandemic and other flu seasons. METHODS: In a cohort of individuals enrolled in pharmacy benefit plans, we used a multivariate logistic regression model to measure associations between subscriber characteristics and filling a prescription for oseltamivir during 3 flu seasons (October 2006-May 2007, October 2007-May 2008, and October 2008-May 2010). In 19 states with county-level influenza rates reported, we controlled for disease burden. RESULTS: Approximately 56 million subscribers throughout the United States were included in 1 or more study periods. During pandemic flu, beneficiaries in the highest income category had 97% greater odds of receiving oseltamivir than those in the lowest category (P < .001). After we controlled for disease burden, subscribers in the 2 highest income categories had 2.18 and 1.72 times the odds of receiving oseltamivir compared with those in the lowest category (P < .001 for both). CONCLUSIONS: Income was a stronger predictor of oseltamivir receipt than prevalence of influenza. These findings corroborate concerns about equity of treatment in pandemics, and they call for improved approaches to distributing potentially life-saving treatments.
OBJECTIVES: We assessed the relationship between individual characteristics and receipt of oseltamivir (Tamiflu) in the United States during the H1N1 pandemic and other flu seasons. METHODS: In a cohort of individuals enrolled in pharmacy benefit plans, we used a multivariate logistic regression model to measure associations between subscriber characteristics and filling a prescription for oseltamivir during 3 flu seasons (October 2006-May 2007, October 2007-May 2008, and October 2008-May 2010). In 19 states with county-level influenza rates reported, we controlled for disease burden. RESULTS: Approximately 56 million subscribers throughout the United States were included in 1 or more study periods. During pandemic flu, beneficiaries in the highest income category had 97% greater odds of receiving oseltamivir than those in the lowest category (P < .001). After we controlled for disease burden, subscribers in the 2 highest income categories had 2.18 and 1.72 times the odds of receiving oseltamivir compared with those in the lowest category (P < .001 for both). CONCLUSIONS: Income was a stronger predictor of oseltamivir receipt than prevalence of influenza. These findings corroborate concerns about equity of treatment in pandemics, and they call for improved approaches to distributing potentially life-saving treatments.
Authors: Lori Uscher-Pines; Patrick S Duggan; Joshua P Garoon; Ruth A Karron; Ruth R Faden Journal: Hastings Cent Rep Date: 2007 Jul-Aug Impact factor: 2.683
Authors: Sharon K Greene; David K Shay; Ruihua Yin; Natalie L McCarthy; Roger Baxter; Michael L Jackson; Steven J Jacobsen; James D Nordin; Stephanie A Irving; Allison L Naleway; Jason M Glanz; Tracy A Lieu Journal: Influenza Other Respir Viruses Date: 2012-06-11 Impact factor: 4.380
Authors: Stella G Muthuri; Puja R Myles; Sudhir Venkatesan; Jo Leonardi-Bee; Jonathan S Nguyen-Van-Tam Journal: J Infect Dis Date: 2012-11-29 Impact factor: 5.226
Authors: Philip Blumenshine; Arthur Reingold; Susan Egerter; Robin Mockenhaupt; Paula Braveman; James Marks Journal: Emerg Infect Dis Date: 2008-05 Impact factor: 6.883